Written procedures to prevent contamination of drug substance are not followed.
Inspection Record
Cook Pharmica LLC — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Sufficient controls to prevent unauthorized changes to data stored on your firm’s HPLC and GC ' |computer systems are inadequate.
There is a lack ofquality oversight in the review ofrecords and procedures followed indrug substance manufacture.
Corrective actions do not include implementation ofadequate procedures to prevent similar — deviations from recurring.
There is an unacceptably high number ofmold recoveries in the classified rooms used for manufacture of bulk drug substance.
A record as of the US FDA document published on 2018-09-10. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.